Do 5α-reductase inhibitors prevent secondary benign prostate hyperplasia-related urinary retention?

Chi Fong Lu, Chun You Chen, Liang Ming Lee, Ke Hsun Lin, Yung Wei Lin, Chi Hao Hsiao, Yu Ching Wen

研究成果: 雜誌貢獻文章

摘要

Objective: The objective of this study is to determine whether 5α-reductase inhibitors (5ARIs) prevent secondary benign prostate hyperplasia (BPH)-related acute urinary retention (AUR) after the first episode of urine retention. Materials and Methods: In total, 1161 patients were enrolled using the International Classification of Diseases, Ninth Revision (ICD-9) codes as having AUR (ICD-9 code 788.20) and BPH, with or without lower urinary tract symptoms (ICD-9 codes 600.0 and 600.1) between January 2006 and June 2016. After excluding patients with bladder and external sphincter dysfunction, we enrolled 128 patients in this study. Patients were divided into two groups: Group 1 comprising 33 patients receiving 5ARI (dutasteride) and α-blocker treatment, and Group 2 comprising 95 patients receiving α-blocker treatment alone. Patient characteristics, namely, age, prostate size, maximal urinary flow rate (Qmax), prostate-specific antigen (PSA) level, and duration of dutasteride treatment, were recorded and compared. Patients were followed for at least 6 months to a maximum period of 24 months if no event occurred. Events of secondary BPH-related AUR and surgery were recorded. Results: All patient characteristics, except for prostate size, were similar between the two groups (Group 1 vs. Group 2: 65.0 vs. 36.9 mL, P = 0.001). In total, 43 patients (32%) experienced secondary AUR within 24 months. The rate of secondary BPH-related AUR was significantly lower in the Group 1 than in the Group 2 (18.2% vs. 39.4%, P = 0.030). The rate of BPH-related surgery was lower in the Group 1 (9.1% vs. 14.9%, P = 0.410), although the difference was not significant. Prostate size and PSA levels were significantly lower in the Group 1 (23.5%) than in the Group 2 (60.4%) (P < 0.001). Conclusions: Using 5ARIs to treat patients with first episodes of BPH-related AUR significantly prevents secondary AUR.
原文英語
頁(從 - 到)86-90
頁數5
期刊Urological Science
29
發行號2
DOIs
出版狀態已發佈 - 三月 1 2018

指紋

Urinary Retention
Hyperplasia
Prostate
Oxidoreductases
International Classification of Diseases
Prostate-Specific Antigen
Lower Urinary Tract Symptoms
Urinary Bladder
Therapeutics
Urine

ASJC Scopus subject areas

  • Urology

引用此文

Do 5α-reductase inhibitors prevent secondary benign prostate hyperplasia-related urinary retention? / Lu, Chi Fong; Chen, Chun You; Lee, Liang Ming; Lin, Ke Hsun; Lin, Yung Wei; Hsiao, Chi Hao; Wen, Yu Ching.

於: Urological Science, 卷 29, 編號 2, 01.03.2018, p. 86-90.

研究成果: 雜誌貢獻文章

@article{09f2d54f7e604700aa9d05952f0ec8f1,
title = "Do 5α-reductase inhibitors prevent secondary benign prostate hyperplasia-related urinary retention?",
abstract = "Objective: The objective of this study is to determine whether 5α-reductase inhibitors (5ARIs) prevent secondary benign prostate hyperplasia (BPH)-related acute urinary retention (AUR) after the first episode of urine retention. Materials and Methods: In total, 1161 patients were enrolled using the International Classification of Diseases, Ninth Revision (ICD-9) codes as having AUR (ICD-9 code 788.20) and BPH, with or without lower urinary tract symptoms (ICD-9 codes 600.0 and 600.1) between January 2006 and June 2016. After excluding patients with bladder and external sphincter dysfunction, we enrolled 128 patients in this study. Patients were divided into two groups: Group 1 comprising 33 patients receiving 5ARI (dutasteride) and α-blocker treatment, and Group 2 comprising 95 patients receiving α-blocker treatment alone. Patient characteristics, namely, age, prostate size, maximal urinary flow rate (Qmax), prostate-specific antigen (PSA) level, and duration of dutasteride treatment, were recorded and compared. Patients were followed for at least 6 months to a maximum period of 24 months if no event occurred. Events of secondary BPH-related AUR and surgery were recorded. Results: All patient characteristics, except for prostate size, were similar between the two groups (Group 1 vs. Group 2: 65.0 vs. 36.9 mL, P = 0.001). In total, 43 patients (32{\%}) experienced secondary AUR within 24 months. The rate of secondary BPH-related AUR was significantly lower in the Group 1 than in the Group 2 (18.2{\%} vs. 39.4{\%}, P = 0.030). The rate of BPH-related surgery was lower in the Group 1 (9.1{\%} vs. 14.9{\%}, P = 0.410), although the difference was not significant. Prostate size and PSA levels were significantly lower in the Group 1 (23.5{\%}) than in the Group 2 (60.4{\%}) (P < 0.001). Conclusions: Using 5ARIs to treat patients with first episodes of BPH-related AUR significantly prevents secondary AUR.",
keywords = "Benign prostate hyperplasia, dutasteride, secondary acute urine retention",
author = "Lu, {Chi Fong} and Chen, {Chun You} and Lee, {Liang Ming} and Lin, {Ke Hsun} and Lin, {Yung Wei} and Hsiao, {Chi Hao} and Wen, {Yu Ching}",
year = "2018",
month = "3",
day = "1",
doi = "10.4103/UROS.UROS_6_17",
language = "English",
volume = "29",
pages = "86--90",
journal = "Urological Science",
issn = "1879-5226",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Do 5α-reductase inhibitors prevent secondary benign prostate hyperplasia-related urinary retention?

AU - Lu, Chi Fong

AU - Chen, Chun You

AU - Lee, Liang Ming

AU - Lin, Ke Hsun

AU - Lin, Yung Wei

AU - Hsiao, Chi Hao

AU - Wen, Yu Ching

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Objective: The objective of this study is to determine whether 5α-reductase inhibitors (5ARIs) prevent secondary benign prostate hyperplasia (BPH)-related acute urinary retention (AUR) after the first episode of urine retention. Materials and Methods: In total, 1161 patients were enrolled using the International Classification of Diseases, Ninth Revision (ICD-9) codes as having AUR (ICD-9 code 788.20) and BPH, with or without lower urinary tract symptoms (ICD-9 codes 600.0 and 600.1) between January 2006 and June 2016. After excluding patients with bladder and external sphincter dysfunction, we enrolled 128 patients in this study. Patients were divided into two groups: Group 1 comprising 33 patients receiving 5ARI (dutasteride) and α-blocker treatment, and Group 2 comprising 95 patients receiving α-blocker treatment alone. Patient characteristics, namely, age, prostate size, maximal urinary flow rate (Qmax), prostate-specific antigen (PSA) level, and duration of dutasteride treatment, were recorded and compared. Patients were followed for at least 6 months to a maximum period of 24 months if no event occurred. Events of secondary BPH-related AUR and surgery were recorded. Results: All patient characteristics, except for prostate size, were similar between the two groups (Group 1 vs. Group 2: 65.0 vs. 36.9 mL, P = 0.001). In total, 43 patients (32%) experienced secondary AUR within 24 months. The rate of secondary BPH-related AUR was significantly lower in the Group 1 than in the Group 2 (18.2% vs. 39.4%, P = 0.030). The rate of BPH-related surgery was lower in the Group 1 (9.1% vs. 14.9%, P = 0.410), although the difference was not significant. Prostate size and PSA levels were significantly lower in the Group 1 (23.5%) than in the Group 2 (60.4%) (P < 0.001). Conclusions: Using 5ARIs to treat patients with first episodes of BPH-related AUR significantly prevents secondary AUR.

AB - Objective: The objective of this study is to determine whether 5α-reductase inhibitors (5ARIs) prevent secondary benign prostate hyperplasia (BPH)-related acute urinary retention (AUR) after the first episode of urine retention. Materials and Methods: In total, 1161 patients were enrolled using the International Classification of Diseases, Ninth Revision (ICD-9) codes as having AUR (ICD-9 code 788.20) and BPH, with or without lower urinary tract symptoms (ICD-9 codes 600.0 and 600.1) between January 2006 and June 2016. After excluding patients with bladder and external sphincter dysfunction, we enrolled 128 patients in this study. Patients were divided into two groups: Group 1 comprising 33 patients receiving 5ARI (dutasteride) and α-blocker treatment, and Group 2 comprising 95 patients receiving α-blocker treatment alone. Patient characteristics, namely, age, prostate size, maximal urinary flow rate (Qmax), prostate-specific antigen (PSA) level, and duration of dutasteride treatment, were recorded and compared. Patients were followed for at least 6 months to a maximum period of 24 months if no event occurred. Events of secondary BPH-related AUR and surgery were recorded. Results: All patient characteristics, except for prostate size, were similar between the two groups (Group 1 vs. Group 2: 65.0 vs. 36.9 mL, P = 0.001). In total, 43 patients (32%) experienced secondary AUR within 24 months. The rate of secondary BPH-related AUR was significantly lower in the Group 1 than in the Group 2 (18.2% vs. 39.4%, P = 0.030). The rate of BPH-related surgery was lower in the Group 1 (9.1% vs. 14.9%, P = 0.410), although the difference was not significant. Prostate size and PSA levels were significantly lower in the Group 1 (23.5%) than in the Group 2 (60.4%) (P < 0.001). Conclusions: Using 5ARIs to treat patients with first episodes of BPH-related AUR significantly prevents secondary AUR.

KW - Benign prostate hyperplasia

KW - dutasteride

KW - secondary acute urine retention

UR - http://www.scopus.com/inward/record.url?scp=85048359197&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048359197&partnerID=8YFLogxK

U2 - 10.4103/UROS.UROS_6_17

DO - 10.4103/UROS.UROS_6_17

M3 - Article

AN - SCOPUS:85048359197

VL - 29

SP - 86

EP - 90

JO - Urological Science

JF - Urological Science

SN - 1879-5226

IS - 2

ER -